Literature DB >> 34853060

Hyperkalemia with Mineralocorticoid Receptor Antagonist Use in People with CKD: Understanding and Mitigating the Risks.

Murray Epstein1, Roberto Pecoits-Filho2,3, Catherine M Clase4, Manish M Sood5,6,7,8, Csaba P Kovesdy9,10.   

Abstract

Entities:  

Keywords:  aldosterone; chronic kidney disease; diabetic nephropathy; hyperkalemia

Mesh：

Substances：

Year:  2021        PMID： 34853060      PMCID： PMC8975031          DOI： 10.2215/CJN.13541021

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  9 in total

1.  Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Catherine M Clase; Juan-Jesus Carrero; David H Ellison; Morgan E Grams; Brenda R Hemmelgarn; Meg J Jardine; Csaba P Kovesdy; Gregory A Kline; Gregor Lindner; Gregorio T Obrador; Biff F Palmer; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Roberto Pecoits-Filho
Journal:  Kidney Int       Date:  2019-10-10       Impact factor: 10.612

Review 2.  Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena.

Authors:  Murray Epstein
Journal:  Kidney Int Suppl (2011)       Date:  2016-03-14

3.  Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.

Authors:  Bertram Pitt; Gerasimos Filippatos; Rajiv Agarwal; Stefan D Anker; George L Bakris; Peter Rossing; Amer Joseph; Peter Kolkhof; Christina Nowack; Patrick Schloemer; Luis M Ruilope
Journal:  N Engl J Med       Date:  2021-08-28       Impact factor: 91.245

4.  Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.

Authors:  David N Juurlink; Muhammad M Mamdani; Douglas S Lee; Alexander Kopp; Peter C Austin; Andreas Laupacis; Donald A Redelmeier
Journal:  N Engl J Med       Date:  2004-08-05       Impact factor: 91.245

5.  Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors.

Authors:  Murray Epstein; Nancy L Reaven; Susan E Funk; Karen J McGaughey; Nina Oestreicher; John Knispel
Journal:  Am J Manag Care       Date:  2015-09       Impact factor: 2.229

6.  Ambulatory Treatments for RAAS Inhibitor-Related Hyperkalemia and the 1-Year Risk of Recurrence.

Authors:  Gregory L Hundemer; Robert Talarico; Navdeep Tangri; Silvia J Leon; Sarah E Bota; Emily Rhodes; Greg A Knoll; Manish M Sood
Journal:  Clin J Am Soc Nephrol       Date:  2021-02-19       Impact factor: 8.237

7.  Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.

Authors:  George L Bakris; Rajiv Agarwal; Stefan D Anker; Bertram Pitt; Luis M Ruilope; Peter Rossing; Peter Kolkhof; Christina Nowack; Patrick Schloemer; Amer Joseph; Gerasimos Filippatos
Journal:  N Engl J Med       Date:  2020-10-23       Impact factor: 91.245

8.  The RALES Legacy and Finerenone Use on CKD Patients.

Authors:  José A Moura-Neto; Claudio Ronco
Journal:  Clin J Am Soc Nephrol       Date:  2021-08-06       Impact factor: 10.614

9.  Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.

Authors:  Bertram Pitt; Lars Kober; Piotr Ponikowski; Mihai Gheorghiade; Gerasimos Filippatos; Henry Krum; Christina Nowack; Peter Kolkhof; So-Young Kim; Faiez Zannad
Journal:  Eur Heart J       Date:  2013-05-27       Impact factor: 29.983
  9 in total
  1 in total

Review 1.  Efficacy and Safety of Finerenone in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

Authors:  Ming-Zhu Zhang; Wujisiguleng Bao; Qi-Yan Zheng; Ya-Hui Wang; Lu-Ying Sun
Journal:  Front Pharmacol       Date:  2022-02-07       Impact factor: 5.810
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.